BioLineRx (BLRX) Gains from Investment Securities (2014 - 2026)
BioLineRx (BLRX) posted quarterly Gains from Investment Securities of -$1.1 million for Q4 2025, up 80.46% year-over-year from -$584630.9 in Q4 2024, and up 6.97% quarter-over-quarter from -$1.1 million in Q3 2025.
Powered by 
Analysis
BioLineRx (BLRX) Gains from Investment Securities (2014 - 2026) Analysis & Trends
BioLineRx's Gains from Investment Securities history runs 12 years deep, the most recent figure standing at -$1.1 million for Q4 2025.
- In Q4 2025, Gains from Investment Securities rose 80.46% year-over-year to -$1.1 million; the TTM figure through Dec 2025 stood at -$8.6 million (up 54.66% YoY), while the FY2025 annual figure was -$8.6 million, up 54.66% from the prior year.
- Gains from Investment Securities for Q4 2025 stood at -$1.1 million, up from -$1.1 million in the prior quarter.
- The five-year high for Gains from Investment Securities was $7.8 million in Q2 2023, with the low at -$8.4 million in Q2 2024.
- The 5-year median for Gains from Investment Securities is -$1.1 million (2022), against an average of -$1.0 million.
- The sharpest annual moves came in 2023 and 2024: Gains from Investment Securities surged 1966.75% in 2023, then tumbled 246.18% in 2024.
- BioLineRx's Gains from Investment Securities stood at -$2.2 million in 2021, then sank by 69.31% to -$3.6 million in 2022, then climbed by 20.1% to -$2.9 million in 2023, then plunged by 85.24% to -$5.4 million in 2024, then soared by 80.46% to -$1.1 million in 2025.
- Business Quant data shows BLRX's Gains from Investment Securities at -$1.1 million in Q4 2025, -$1.1 million in Q3 2025, and $1.9 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn |
| 10 | BioLineRx | 6.46 Bn | 6.46 Bn | 235,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 682,000.00 |
| Mar 31, 2026 | -436,000.00 |
| Dec 31, 2025 | -1.06 Mn |
| Sep 30, 2025 | -1.13 Mn |
| Jun 30, 2025 | 1.90 Mn |
| Mar 31, 2025 | -8.31 Mn |
| Dec 31, 2024 | -5.40 Mn |
| Sep 30, 2024 | -722,000.00 |
| Jun 30, 2024 | -8.40 Mn |
| Mar 31, 2024 | -4.44 Mn |
| Dec 31, 2023 | -2.91 Mn |
| Sep 30, 2023 | 3.13 Mn |
| Jun 30, 2023 | 7.80 Mn |
| Mar 31, 2023 | 3.04 Mn |
| Dec 31, 2022 | -3.65 Mn |
| Sep 30, 2022 | -1.11 Mn |
| Jun 30, 2022 | -418,000.00 |
| Mar 31, 2022 | -1.26 Mn |
| Dec 31, 2021 | -2.15 Mn |
| Sep 30, 2021 | -799,000.00 |